ClinicalTrials.gg
Active, not recruitingNCT06212297Updated Jun 29, 2025

Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

A Phase 1/2 interventional study of LX101 in Inherited Retinal Dystrophy, sponsored by Innostellar Biotherapeutics Co.,Ltd. Active, not recruiting at 1 site in China. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2025-06-29.

Sponsored by Innostellar Biotherapeutics Co.,Ltd · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Sep 2023, registered Dec 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Retinal Dystrophies with a site in China — 6 open to participants now, 9 under way, 1 of them phase 3. Retinal Dystrophies · China.

Started
2023
with 1 other
Phase 1/2
2 of 10
1 open now
Registered
4th of 10
by date
Lead sponsor
3 of 10
Innostellar Biotherapeutics Co.,Ltd

Among the 10 studies in Retinal Dystrophies with a site in China, this one is one of 2 that started in 2023, is one of 2 in phase 1/2, and was the 4th registered.

Retinal Dystrophies

60 studies on the registry are indexed under Retinal Dystrophies; 20 are open to participants now.

Browse Retinal Dystrophies studies →

Open to participants now

6 of the 10 studies in Retinal Dystrophies with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 17 Retinal Dystrophies studies recruiting now, 11 (65%) set no upper age limit and 3 (18%) stop at 75 or younger; 6 take children under 18; 5 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Retinal Dystrophies with a site in China, or all of them as a file.
02

Study summary

Up to nine subjects who have participated in the earlier LX101 clinical study, and who meet all study eligibility criteria, will receive LX101 administration in the previously uninjected, contralateral eye to evaluate the safety of bilateral, sequential subretinal administration of LX101.

03

Conditions studied

  • Inherited Retinal Dystrophy

Browse trials for

Keywords

  • RPE65 Mutations
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Prior subretinal administration of LX101 (unilateral)

≥ 6 years old Signed written

Exclusion criteria

Exclusion Criteria:

Prior gene therapy except LX101 Active intraocular or periocular infections Lacking of sufficient surviving retinal cells Prior ocular surgery within six months Retinoid like compounds or precursors were taken within three months Complicating systemic diseases abnormal baseline laboratory values Using of any retinal toxic compounds

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    LX101 Subretinal Administration

    Genetic: LX101

Interventions

  • GeneticLX101

    Subretinal administration of LX101 to the contralateral, previously uninjected eye

06

What researchers measure

Primary outcomes

  1. Safety: Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Incidence of ocular and non-ocular AEs and SAEs following LX102 subretinal injection

    Time frame: 6 months

Secondary outcomes

  1. Full-field Light Sensitivity Threshold (FST) Test

    Changes in light sensitivity from baseline, assessed by FST in log cd.s/m2

    Time frame: 6 months、12 months

  2. Visual Acuity

    Changes in visual acuity from baseline, based on the ability to read letters using the Early Treatment Diabetic Retionpathy Study (ETDRS) chart

    Time frame: 6 months、12 months

  3. Mobility Test

    Changes in functional vision from baseline, determined by mobility test score

    Time frame: 6 months、12 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Feb 2025, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2023
First posted
Jan 18, 2024
StartActual
Sep 12, 2023
Primary completionActual
Feb 6, 2025
CompletionEst.
Mar 2029
Last update
Jun 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06212297
Lead sponsor
Innostellar Biotherapeutics Co.,Ltd
Responsible party
Sponsor
First posted
Jan 18, 2024
Start date
Sep 12, 2023
Primary completion
Feb 6, 2025
Completion
Mar 2029 (estimated)
Last update
Jun 29, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion